LKLaura Kähäri

Laura Kähäri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Laura Kähäri has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The p. Ser143Pro lamin A/C mutation leads to dilated cardiomyopathy and activates the unfolded protein response pathway in a knock‐in mouse model

    by Fanny Lindholm, Gun West, Laura Virtanen, Laura Kähäri, Mia Ståhle, Wail Nammas, Carl‐Gustaf A Stenvall, Maria Bouvy‐Liivrand, Fu‐Ping Zhang, Petra Sipilä, et al.

    Dilated cardiomyopathy (DCM) is characterized by progressive ventricular dilation, systolic dysfunction, and an increased risk of arrythmias and sudden cardiac arrest. Variants in the LMNA gene, which encodes the nuclear lamins A and C, have been linked to the familial form of the disease and the founder variant p.Ser143Pro is particularly common among Finnish patients with DCM. To elucidate the complex and poorly understood pathogenic mechanisms behind LMNA ‐related DCM, we generated a mouse model carrying the p.Ser143Pro mutation in the Lmna gene. All genetically modified mice appeared normal at birth. However, based on echocardiography, necropsy, natriuretic peptide B ( Nppb ) expression levels, and histopathological data, homozygous males developed progressive left ventricular dilatation, myocardial fibrosis, and cardiac failure after 6 months of age, with all succumbing before 10 months. A reduced disease penetrance was observed in heterozygous male and homozygous female mice, with one‐year survival rates of 40% and 60%, respectively. No signs of skeletal myopathy were observed in mice carrying the mutation. Whole‐transcriptome RNA sequencing analysis of left ventricular cardiac tissue from asymptomatic two‐month‐old homozygous male mice revealed an upregulation of classical heart failure markers, such as natriuretic peptide A ( Nppa ) and myosin heavy chain 7 ( Myh7 ), and an elevated unfolded protein response signaling, as shown by elevated DNA damage inducible transcript 3 ( Ddit3 ), BAG cochaperone 3 ( Bag3 ) and CCAAT enhancer binding protein beta ( Cebpb ) levels. In conclusion, p.Ser143Pro‐ Lmna mice closely mimic the clinical phenotype observed in patients with the p.Ser143Pro LMNA variant and offer a valuable in vivo model for investigating the underlying pathogenic mechanisms of LMNA ‐related DCM. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

  • COVID-19 vaccine type controls stromal reprogramming in draining lymph nodes

    by Ruth Fair-Mäkelä, Pinja Thorén, Joni Näsiaho, Pia Sundqvist, Irina Piiroinen, Laura Kähäri, Ilkka Julkunen, Johanna Ivaska, Elin Hub, Antal Rot, et al.

    Lymph node (LN) stromal cells are critical regulators of immune reactions, yet their responses to different SARS-CoV-2 vaccines remain unexplored. Here, we immunized mice with clinically approved gene- and protein-based COVID-19 vaccines targeting viral spike (S) protein and analyzed the draining LN stroma using multimodal bioimaging, single-cell transcriptomics, and functional studies. We found that messenger RNA and adenovirus vector vaccines transfected lymphatic endothelial cell and fibroblastic reticular cell subsets in vivo and led to early local S protein production in the draining LN in a vaccine-specific manner. The vaccines induced rapid transcriptomic reprogramming of the LN stromal cells, which functionally altered scavenging and parenchymal transfer of lymph-borne antigens, formation of chemokine gradients, and migration of eosinophils within LNs. Thus, distinct vaccine formulations targeting S protein differentially prime the draining LN stromal cells before the arrival of migratory dendritic cells bearing immunogens.